IASO208 Cleared for U.S. In Vivo CAR-T Testing

Company IASO Bio Event Type IND Clearance Modality In Vivo CAR-T (Lentiviral Vector, Third-Generation, Self-Inactivating) Asset IASO208 Target CD20 Disease Area Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Summary FDA cleared IASO208, a CD20-directed in vivo CAR-T candidate built on a replication-incompetent, self-inactivating third-generation lentiviral vector,…